An analysis of brand-name prescription drug prices shows it's been business as usual for drugmakers, with far more price hikes than cuts. The number of increases slowed somewhat and were not quite as steep as in past years.
Gilead will start selling the generics for chronic hepatitis C in January at a $24,000 list price, a significant discount compared to the price for its branded alternatives, which can cost nearly $100,000 for a full course of treatment.
Instagram has begun using some drug-related hashtags, such as “opioid” and “uppers,” to steer users of the app to information about opioid treatment and recovery.
A push by Big Pharma to claw back Medicare Part D donut hole money as part of the opioids package has hit sharp Democratic opposition.
California's insurance commissioner accused pharmaceutical giant AbbVie of illegally plying doctors with cash, gifts and services to prescribe Humira, tainting their relationship with patients and driving up insurance costs.
The Food and Drug Administration is considering a new payment model aimed at encouraging drugmakers to develop new antibiotics.
The FDA wants to launch a national study to analyze how well doctors understand drug advertising information before they prescribe medications, citing limited data on the issue.
A proposal to sharply cut the 340B drug discount program drew some 1,400 comments when the Trump administration announced its plan last year. But a review of the responses found that some individuals had no memory of signing anything, much less sending their opinions about it.
The price of insulin in the U.S. has more than doubled since 2012 alone. That's put the life-saving hormone out of reach for some people with diabetes. It has left others scrambling for solutions to afford the one thing they need to live.
More than half of Americans tested by Quest Diagnostics in 2017 misused prescription drugs, a statistic that has remained relatively flat and suggests that medication adherence is more difficult as the opioid epidemic swells.
Purdue Pharma, a company whose prescription opioid marketing practices are being blamed for sparking the addiction and overdose crisis, says it's helping to fund an effort to make a lower-cost overdose antidote.
Authorities are ramping up their efforts to identify fentanyl flooding into the U.S. from China, control the ingredients used to make the deadly synthetic opioid, and prosecute and eliminate the manufacturers.